ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,898,855 | +2.7% | 169,787 | -2.1% | 1.01% | +14.9% |
| Q2 2023 | $15,481,553 | -6.8% | 173,463 | +12.0% | 0.88% | -6.9% |
| Q1 2023 | $16,611,345 | -6.7% | 154,928 | +6.3% | 0.94% | -7.5% |
| Q4 2022 | $17,799,104 | +26.3% | 145,739 | +6.8% | 1.02% | +25.0% |
| Q3 2022 | $14,089,000 | -7.0% | 136,445 | -16.3% | 0.82% | +11.6% |
| Q2 2022 | $15,151,000 | -4.3% | 162,988 | +20.8% | 0.73% | +16.0% |
| Q1 2022 | $15,832,000 | +17.9% | 134,900 | +35.1% | 0.63% | +32.3% |
| Q4 2021 | $13,434,000 | +9.8% | 99,861 | +30.1% | 0.48% | +5.5% |
| Q3 2021 | $12,236,000 | +131.5% | 76,766 | +91.1% | 0.45% | +140.4% |
| Q2 2021 | $5,285,000 | +2.1% | 40,173 | 0.0% | 0.19% | +11.2% |
| Q1 2021 | $5,177,000 | -26.1% | 40,173 | -4.3% | 0.17% | -31.3% |
| Q4 2020 | $7,002,000 | +103.6% | 41,983 | +88.4% | 0.25% | +77.0% |
| Q3 2020 | $3,439,000 | – | 22,287 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |